COLITIS MODELS
Critical colitis studies call for the best in vivo models.
Chronic inflammation of the inner lining of the colon can be caused by many types of insults: invasion of the colon wall by collagen or lymphocytic white blood cells, Inflammatory Bowel Disease (IBD), colonic ischemia; the list goes on. The impact that colitis has on the Quality of Life (QoL) of patients suffering from it is too great to be disregarded: A study of a European cohort suffering from moderate to severe ulcerative colitis reported having poorer health-related QoL, increased morbidity, and severe impairment of both personal and social activities1.
At PharmaLegacy, we understand the need for the development of better anti-inflammatory treatments for all forms of colitis. This is why as a CRO, we are committed to providing you with all the tools necessary to discover, develop and gain approval for your colitis pipelines.
With you throughout the race for better treatments, and all the way to the finish line. PharmaLegacy.
MODELS / SERVICES
PharmaLegacy Models and Research Tools
IBD models can either be induced or spontaneously occurring in animals. Models include: (i) animals treated with agents that promote intestinal inflammation, (ii) rodents that have been genetically manipulated and (iii) immunodeficient animals. As the onset of inflammation is immediate and the procedure is relatively straightforward, chemically-induced models of intestinal inflammation have become the most commonly used IBD animal models. At PharmaLegacy we have validated a complete set of IBD models in rodents.
Related Capabilities
· Antigen-specific T-cell responses
· Detection of tissue cytokine levels (protein, mRNA) by ELISA or real time RT-PCR
· Histopathology and immunohistochemistry in colonic tissues
· Flow cytometry analysis of cell functions including intracellular staining of cytokines
· Detection of signal transduction by western blot
Case Study - DNBS-Induced IBD in Wistar Rats
Animal: Wistar rats
Reagent: DNBS, Sulfasalazine
Results: Effect of Sulfasalazine on DNBS-Induced Colitis
Effect of Sulfasalazine on MPO in Colon Tissue
PharmaLegacy Models and Research Tools
IBD models can be either induced or spontaneously occurring in animals. Models include: (i) animals treated with agents that promote intestinal inflammation, (ii) rodents that have been genetically manipulated and (iii) immunodeficient animals. As the onset of inflammation is immediate and the procedure is relatively straightforward, chemically induced models of intestinal inflammation have become the most commonly used IBD animal models. At PharmaLegacy we have validated a complete set of IBD models in rodents.
Related Capabilities:
· Antigen-specific T-cell responses
· Detection of tissue cytokine levels (protein, mRNA) by ELISA or real time RT-PCR
· Histopathology and immunohistochemistry in colonic tissues
· Flow cytometry analysis of cell functions including intracellular staining of cytokines
· Detection of signal transduction by western blot
Exceptional Preclinical Pharmacology Studies:
With a complete set of IBD models, our scientists specialize in both immunology and pharmacology; they both design and execute various IBD studies for our clients.
1. Efficacy studies of drug compounds (clinical symptoms and disease score)
2. Proof of concept studies for early drug development:
· Effects of anti-inflammation: T cell and macrophage migration
· Effects of anti-autoimmune disorder
· Effects of cytokine/chemokine response
· Evaluation of therapeutic profile and potentials
3. Demonstration of differential regulation of disease progression
4. Investigation of the mechanisms of immune tolerance induction
DSS-Induced Acute Colitis in C57BL/6 Mice
Animal: C57BL/6 mice
Reagent: Dextran Sulfate Sodium (DSS)
Effect of CsA on Colon Length, Colon Weight and Body Weight
Effect of CsA on Inflammatory Markers in Colon and Serum
Effect of CsA on Cytokines mRNA in Colon Tissue Colon
Pathology (H&E Staining)
Case Study：Chemotherapy-induced Mucositis in Cynomolgus Monkey
Animal: Cynomolgus monkeys, female
Material: Irinotecan (CPT-11)
Mucositis: Inflammation and ulceration of the SI
Clinical Assessment of Mucositis
White Blood Cell (WBC) and Differential Counts
Similar to the decrease of WBC counts after CPT-11 challenge, Lymph#, Neu# and Eos# were also decreased. ~12 days later, these cells went back to their baseline.
Villi shortening, crypt destruction, and impaired goblet cell mucin production was observed in the model.
Pioneering healthcare solutions:
- Completed over 400 FDA / CFDA IND filings
- Scientific staff with an average of over 15 years of pharmacology experience
- Electronically managed, traceable research data
- 380,000 square feet of facility space
Never settle for less with your drug pipelines. Work with PharmaLegacy.
Can you trust your animal model to provide you with the correct answers?
No animal study can predict with complete certainty how a therapy will perform in human subjects, but it is PharmaLegacy’s job to ensure that you come as close to certainty as possible. Download our brochure on non-human primate (NHP) models and see how PharmaLegacy ensures that your studies utilize the most physiologically relevant models.
We’re ready when you are.
Tell us your pharmacology challenges.
